Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

$AMBS Offer So Much Upside for a Stock Trading Under A Dime

"We believe Amarantus will seek a commercial partner for eltoprazine after the Phase 2b data if successful. There are an estimated 16,000 neurologists in the U.S, about half of which specialize in movement disorders or treat Parkinson’s patients. This is clearly a specialty pharmaceutical promotion. We believe with strong Phase 2b data, Amarantus can partner eltoprazine for $30 to $50 million upfront and $300 to $400 million in total potential. We are using the May 2009 transaction between Acadia Pharma and Biovail for pimavanserin ($30 million upfront + $365 million total potential) as the key basis for what a deal might look like. In May 2009, pimavanserin was coming off positive Phase 2 data and had development potential in PDP, Alzheimer’s disease psychosis, and schizophrenia."


Eltoprazine is only one of the products in $AMBS' pipeline:

http://www.amarantus.com/pipeline